The $15 Drug That Could Rewire the Whole Economy

The Patent Cliff Nobody Covered

On March 20th, 2026, one of the most consequential drug patents in recent memory quietly expired in India. Semaglutide, the molecule behind Ozempic and Wegovy, was suddenly available from generic manufacturers at $15 a month. For context, the best retail price an American consumer can find today comes from Costco, at $499. The standard list price runs closer to $1,000.

This is not a footnote. This is the opening move in a global repricing event, and as Neeta argues in this episode, the economic implications run far deeper than anyone in pharma, food, or finance has fully priced in.

Novo Nordisk's Problem Is Everyone Else's Signal

Novo Nordisk, the Danish company that brought Ozempic to market, once carried a market cap north of $165 billion. It is now down 58% from that peak. Revenue growth, which once looked like a vertical line, has slowed to roughly 11% year over year. The company has already launched a budget brand in India called Extensior, a clear signal that the era of 60 to 70x margins is over.

The more disruptive move is what happens next. Indian generic manufacturers are already cutting deals in Brazil, Turkey, and Canada. Canada is the sleeper here. The moment Americans can see $15 semaglutide just across the northern border, the political and commercial pressure on US pricing becomes very hard to contain.

The question, as Neeta frames it, stops being about price and starts being about control of the pipeline.

The Science Just Got More Interesting

Timing is everything, and the patent cliff arrived alongside a cluster of research findings that significantly expand what we thought we knew about these drugs.

The Cleveland Clinic released a study of 8,000 patients showing just 0.5% weight regain, a dramatic improvement over earlier trial data where patients who stopped the drug rebounded to near their original weight quickly. A Veterans Affairs study of 600,000 patients found GLP-1s cut substance use disorder risk by 15 to 20% across cocaine, alcohol, and cannabis. A Finnish study found fewer depression and anxiety episodes and lower rates of psychiatric hospitalization among users.

Scientists believe all of this reflects the same underlying mechanism: GLP-1s appear to rewire the dopamine reward system. That is not a small thing. The implications reach well beyond waistlines.

Where AI Enters the Picture

Two AI developments are worth watching closely. First, researchers have found that AI models outperform physicians at determining optimal GLP-1 dosing, which points directly to higher efficacy as these tools become standard. Second, a Stanford team used AI to identify a naturally occurring molecule that mimics semaglutide's effects without causing muscle loss, one of the drug's most significant side effects. Neither of these stories got much attention. Both matter enormously for the drug's long-term trajectory.

The Slow-Motion Shock to the Vice Economy

Here is where the macro picture gets genuinely strange. Goldman Sachs projects 60 million Americans on GLP-1s by 2028, a level of adoption that could add 1% to US GDP simply by returning people sidelined by chronic health conditions back to work. Circana estimates GLP-1 households could account for 35% of all US food and beverage spending by 2030.

A Nielsen IQ and Washington Post analysis found GLP-1 users cut alcohol consumption by 14.5% and sharply increased non-alcoholic beverage intake. Combine that with the VA data on substance use and the Finnish psychiatric findings, and a pattern emerges: a slow-motion demand shock is heading toward the vice industry.

Alcohol, tobacco, casinos, sports betting, fast food engineered around compulsive consumption. These are industries built on reliable human cravings. None of them have seriously modeled a world where 60 million Americans have had their reward systems quietly recalibrated.

The addiction recovery sector alone is a $600 billion market. Analysts have not begun to price what happens to that industry if the underlying demand changes structurally.

What Comes Next

The commodity price of semaglutide is heading toward the floor. AI is making the drug more precise and spawning next-generation alternatives. The behavioral data is pointing toward changes in how Americans eat, drink, and spend that will ripple through entire sectors.

The real variable is speed. As generics spread from India to Canada and beyond, how fast does adoption accelerate, and which industries run out of time to adapt? That is the question worth watching, and it is one that most of the market is not yet asking.